Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.

CONCLUSION: Taken together, our findings suggest that DHM prevents progression of AD-like pathology through inhibition of NLRP3 inflammasome-based microglia-mediated neuroinflammation and may be a promising therapeutic drug for treating AD. PMID: 29869390 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29869390?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - June 4, 2018 Category: Neuroscience Authors: Feng J, Wang J, Du Y, Liu Y, Zhang W, Chen J, Liu Y, Zheng M, Wang K, He G Tags: CNS Neurosci Ther Source Type: research